Relay Therapeutics Inc (RLAY)

Currency in USD
3.57
+0.03(+0.85%)
Closed·
3.60+0.03(+0.84%)
·
RLAY Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RLAY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.503.57
52 wk Range
1.7810.72
Key Statistics
Prev. Close
3.57
Open
3.51
Day's Range
3.5-3.57
52 wk Range
1.78-10.72
Volume
563.14K
Average Volume (3m)
1.91M
1-Year Change
-51.24%
Book Value / Share
3.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RLAY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.10
Upside
+266.95%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings upwards for the upcoming period

Relay Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Relay Therapeutics Inc Company Profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics Inc SWOT Analysis


AI-Driven Innovation
Explore Relay Therapeutics' pioneering approach to drug discovery, leveraging artificial intelligence to accelerate development of precision medicines for cance
RLY-2608 Breakthrough
Delve into the promising Phase 2 results of RLY-2608, a mutant-selective PI3Ka inhibitor showing significant potential in breast cancer treatment
Strategic Positioning
Analysts maintain a bullish outlook with price targets ranging from $4 to $29, reflecting confidence in Relay's market position and growth potential
Financial Fortitude
Learn how Relay's cost-cutting measures and strong balance sheet aim to extend cash runway through 2029, supporting pivotal Phase 3 trial execution
Read full SWOT analysis

Compare RLAY to Peers and Sector

Metrics to compare
RLAY
Peers
Sector
Relationship
P/E Ratio
−2.0x−0.5x−0.6x
PEG Ratio
−0.08−0.020.00
Price/Book
0.9x2.5x2.6x
Price / LTM Sales
73.7x8.1x3.3x
Upside (Analyst Target)
267.2%293.2%38.7%
Fair Value Upside
Unlock14.6%5.1%Unlock

Analyst Ratings

10 Buy
2 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 13.10
(+266.95% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.41 / -0.49
Revenue / Forecast
700.00K / 66.67K
EPS Revisions
Last 90 days

RLAY Income Statement

People Also Watch

15.52
KROS
+4.09%
14.140
CRMD
+1.07%
18.07
SRPT
-1.04%
46.03
BMNR
-7.85%

FAQ

What Stock Exchange Does Relay Trade On?

Relay is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Relay?

The stock symbol for Relay is "RLAY."

What Is the Relay Market Cap?

As of today, Relay market cap is 613.78M.

What Is Relay's Earnings Per Share (TTM)?

The Relay EPS (TTM) is -1.92.

When Is the Next Relay Earnings Date?

Relay will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is RLAY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Relay Stock Split?

Relay has split 0 times.

How Many Employees Does Relay Have?

Relay has 197 employees.

What is the current trading status of Relay (RLAY)?

As of 28 Aug 2025, Relay (RLAY) is trading at a price of 3.57, with a previous close of 3.57. The stock has fluctuated within a day range of 3.50 to 3.57, while its 52-week range spans from 1.78 to 10.72.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.